On July 3, 2014, the U. S. Food and Drug Administration granted accelerated approval to belinostat (BELEODAQ, Spectrum Pharmaceuticals, Inc.) for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL).
Due to the growth in health care-related data, we are seeking your ideas that will enhance the availability and utility of the data. Posted from: California Oncology Weekly: June 17, 2014
We’ve been advertising that a new and improved LCD/Medical Policy Search application is coming. The wait is over! On June 13, 2014, you will see and have access to the new LCD/Medical Policy Search Lookup Tool. To assist you in navigating this new tool, we created...
Up-to-Date Resources on the Affordable Care Act (ACA) for Oncology Providers and Their Patients To help inform its members about the effects of ACA implementation on oncology practices, ASCO has established this online resource, which provides details about the law,...
CHOP BOARD PROFILE President Kari A. Young, CPA CHOP President Kari A. Young, CPA, has worked in oncology for over 9 years out of “24 years of experience in executive management, policy, development, strategic planning, organizational development, and technical...
According to the American Academy of Dermatology and the World Health Organization, indoor tanning heightens the risk of developing melanoma by 59 percent, and the risk goes up with each use. Despite these risks, according to the American Cancer Society (ACS),...
